Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof
CA 2538075 C · Owner: The Medicines Company (Leipzig) Gmbh · Inventors: Schweinitz, Andrea; Stuerzebecher, Joerg; Stuerzebecher, Anne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the novel base-substituted benzylamine analogs of general formula (I), wherein A represents P2--P1 with P1 = (A) and P2 = (B) for use as coagulation factor Xa inhibitors. The invention also relates to the production and use of said analogs in the therapy and prophylaxis of cardiovascular diseases and thromboembolic events.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 13, 2004 and granted April 2, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 13, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 13, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.